AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Genes & Diseases Article
PDF (688.8 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review Article | Open Access

Nuclear Magnetic Resonance technique in tumor metabolism

Ting Lia, Pengchi Dengb,( )
College of Chemistry, Sichuan University, Chengdu, China
Analytical & Testing Center, Sichuan University, Chengdu, China

Peer review under responsibility of Chongqing Medical University.

Show Author Information

Abstract

Cancer is one of the most serious diseases that cause an enormous number of deaths all over the world. Tumor metabolism has great discrimination from that of normal tissues. Exploring the tumor metabolism may be one of the best ways to find biomarkers for cancer detection, diagnosis and to provide novel insights into internal physiological state where subtle changes may happen in metabolite concentrations. Nuclear Magnetic Resonance (NMR) technique nowadays is a popular tool to analyze cell extracts, tissues and biological fluids, etc, since it is a relatively fast and an accurate technique to supply abundant biochemical information at molecular levels for tumor research. In this review, approaches in tumor metabolism are discussed, including sample collection, data profiling and multivariate data analysis methods etc. Some typical applications of NMR are also summarized in tumor metabolism.

Keywords

MetabolomicsHigh resolution Magic Angle SpinningMultivariate data analysisNMR techniqueTumor metabolism

References

1

Siegel RL, Miller KD, Jemal A. Cancer statistics. CA A Cancer J Clin. 2015;65(1): 5–29.
Crossref Google Scholar
2

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics. CA A Cancer J Clin. 2012;65(2): 87–108.
Crossref Google Scholar
3

Oken MM, Hocking WG, Kvale PA, et al. Screening by chest radiograph and lung cancer mortality: the prostate, lung, colorectal, and ovarian (plco) randomized trial. JAMA. 2011;306(17): 1865–1873.
Crossref Google Scholar
4
Oken MM, Marcus PM, Hu P, et al. Baseline chest radiograph for lung cancer detection in the randomized prostate, lung, colorectal and ovarian cancer screening trial. J Natl Cancer Inst. December 21, 2005;97(24): 1832–1839.
Crossref
5

Karahalli E, Yilmaz A, Türker H, Özvaran K. Usefulness of various diagnostic techniques during fiberoptic bronchoscopy for endoscopically visible lung cancer: should cytologic examinations be performed routinely? Respiration. 2001;68(6):611–614.
Crossref Google Scholar
6

Berrington de González A, Mahesh M, Kim K, et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Archives Intern Med. 2009;169(22):2071–2077.
Crossref Google Scholar
7
Berrington de González A, Kim KP, Berg CD. Low-dose lung computed tomography screening before age 55: estimates of the mortality reduction required to outweigh the radiation-induced cancer risk. J Med Screen. September 1, 2008;15(3): 153–158.
Crossref
8

Padhani AR, Liu G, Mu-Koh D, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia. 2009;11(2):102–125.
Crossref Google Scholar
9
Chenevert TL, McKeever PE, Ross BD. Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res. September 1, 1997;3(9): 1457–1466.
10

Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006;354(5):496–507.
Crossref Google Scholar
11

Yi CA, Lee KS, Lee HY, et al. Coregistered whole body magnetic resonance imaging-positron emission tomography (MRI-PET) versus PET-computed tomography plus brain MRI in staging resectable lung cancer. Cancer. 2013;119(10):1784–1791.
Crossref Google Scholar
12

Erasmus JJ, Sabloff BS. CT, positron emission tomography, and MRI in staging lung cancer. Clin Chest Med. 2008;29(1):39–57.
Crossref Google Scholar
13

Sugimoto M, Wong DT, Hirayama A, Soga T, Tomita M. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics. 2010;6(1):78–95.
Crossref Google Scholar
14

Claudino WM, Goncalves PH, di Leo A, Philip PA, Sarkar FH. Metabolomics in cancer: a bench-to-bedside intersection. Crit Rev Oncol Hematol. 2012;84(1):1–7.
Crossref Google Scholar
15

Patel S, Ahmed S. Emerging field of metabolomics: big promise for cancer biomarker identification and drug discovery. J Pharm Biomed Anal. 2015;107:63–74.
Crossref Google Scholar
16
Yizhak K, Benyamini T, Liebermeister W, Ruppin E, Shlomi T. Integrating quantitative proteomics and metabolomics with a genome-scale metabolic network model. Bioinformatics. June 15, 2010;26(12): i255-i260.
Crossref
17
Nicholson JK, Wilson ID. High resolution proton magnetic resonance spectroscopy of biological fluids. Prog Nucl Magnetic Reson Spectrosc. 1989/01/01;21(4): 449–501.
Crossref
18
Nambiar PR, Gupta RR, Misra V. An “Omics” based survey of human colon cancer. Mutat Res Fundam Mol Mech Mutagen. 11/10/2010;693(1–2): 3–18.
Crossref
19

Raamsdonk LM, Teusink B, Broadhurst D, et al. A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nat Biotechnol. 2001;19(1):45–50.
Crossref Google Scholar
20

Bino RJ, Hall RD, Fiehn O, et al. Potential of metabolomics as a functional genomics tool. Trends Plant Sci. 2004;9(9):418–425.
Crossref Google Scholar
21

Kell DB. Systems biology, metabolic modelling and metabolomics in drug discovery and development. Drug Discov Today. 2006;11(23):1085–1092.
Crossref Google Scholar
22
Nicholson JK, Lindon JC, Holmes E. ‘Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 1999/01/01;29(11): 1181–1189.
Crossref
23
Dunn WB, Broadhurst DI, Atherton HJ, Goodacre R, Griffin JL. Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chem Soc Rev. 2011/01;40(1): 387–426.
Crossref
24
Bathen TF, Sitter B, Sjøbakk TE, Tessem M-B, Gribbestad IS. Magnetic resonance metabolomics of intact tissue: a biotechnological tool in cancer diagnostics and treatment evaluation. Cancer Res. 2010/09;70(17): 6692–6696.
Crossref
25

Yang J, Xu G, Zheng Y, et al. Diagnosis of liver cancer using HPLC-based metabonomics avoiding false-positive result from hepatitis and hepatocirrhosis diseases. J Chromatogr B. 2004;813(1):59–65.
Crossref Google Scholar
26

Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. Nat Rev Cancer. 2004;4(7):551–561.
Crossref Google Scholar
27

Woo HM, Kim KM, Choi MH, et al. Mass spectrometry based metabolomic approaches in urinary biomarker study of women's cancers. Clin Chim Acta. 2009;400(1):63–69.
Crossref Google Scholar
28
Zürbig P, Mischak H. Capillary Electrophoresis Coupled to Mass Spectrometry for Biomarker Discovery and Diagnosis of Kidney Diseases. 2008
29

Kolch W, Neusüß C, Pelzing M, Mischak H. Capillary electrophoresis–mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom Rev. 2005;24(6):959–977.
Crossref Google Scholar
30

Zhang J, Wei S, Liu L, et al. NMR-based metabolomics study of canine bladder cancer. Biochimica Biophysica Acta (BBA) – Mol Basis Dis. 2012;1822(11):1807–1814.
Crossref Google Scholar
31

Gebregiworgis T, Powers R. Application of NMR metabolomics to search for human disease biomarkers. Comb Chem High Throughput Screen. 2012;15(8):595–610.
Crossref Google Scholar
32

Zira AN, Theocharis SE, Mitropoulos D, Migdalis V, Mikros E. 1H NMR metabonomic analysis in renal cell carcinoma: a possible diagnostic tool. J Proteome Res. 2010;9(8):4038–4044.
Crossref Google Scholar
33

Yang C, Richardson AD, Osterman A, Smith JW. Profiling of central metabolism in human cancer cells by two-dimensional NMR, GC-MS analysis, and isotopomer modeling. Metabolomics. 2008;4(1):13–29.
Crossref Google Scholar
34

de Graaf RA, Behar KL. Quantitative 1H NMR spectroscopy of blood plasma metabolites. Anal Chem. 2003;75(9):2100–2104.
Crossref Google Scholar
35

Wilson M, Davies NP, Brundler M-A, McConville C, Grundy RG, Peet AC. High resolution magic angle spinning 1H NMR of childhood brain and nervous system tumours. Mol Cancer. 2009;8(1):1–11.
Crossref Google Scholar
36

DeFeo EM, Wu C-L, McDougal WS, Cheng LL. A decade in prostate cancer: from NMR to metabolomics. Nat Rev Urol. 2011;8(6):301–311.
Crossref Google Scholar
37

Denkert C, Bucher E, Hilvo M, et al. Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery. Genome Med. 2012;4(4):37.
Crossref Google Scholar
38

Li CW, Kuo YC, Chen CY, et al. Quantification of choline compounds in human hepatic tumors by proton MR spectroscopy at 3T. Magnetic Reson Med. 2005;53(4):770–776.
Crossref Google Scholar
39
Tosi MR, Tugnoli V, Bottura G, Lucchi P, Battaglia A, Giorgianni P. Biochemical characterization of human renal tumors by in vitro nuclear magnetic resonance. J Mol Struct. 5/30/ 2001;565–566: 323–327.
Crossref
40

Zhang X, Xu L, Shen J, et al. Metabolic signatures of esophageal cancer: NMR-based metabolomics and UHPLC-based focused metabolomics of blood serum. Biochimica Biophysica Acta (BBA) – Mol Basis Dis. 2013;1832(8):1207–1216.
Crossref Google Scholar
41

Dumas M-E, Maibaum EC, Teague C, et al. Assessment of analytical reproducibility of 1H NMR spectroscopy based metabonomics for large-scale epidemiological research: the INTERMAP Study. Anal Chem. 2006;78(7):2199–2208.
Crossref Google Scholar
42
Gil AM, de Pinho PG, Monteiro MS, Duarte IF. NMR metabolomics of renal cancer: an overview. Bioanalysis. 2015/09/01;7(18): 2361–2374.
Crossref
43

Liu M, Nicholson JK, Lindon JC. High-resolution diffusion and relaxation edited one-and two-dimensional 1H NMR spectroscopy of biological fluids. Anal Chem. 1996;68(19):3370–3376.
Crossref Google Scholar
44

Martin-Pastor M. Experiments for the editing of singlet peaks and simplification of 1H NMR spectra of complex mixtures. J Agric food Chem. 2014;62(5):1190–1197.
Crossref Google Scholar
45

Katz-Brull R, Margalit R, Bendel P, Degani H. Choline metabolism in breast cancer; 2H-, 13C- and 31P-NMR studies of cells and tumors. Magnetic Reson Mater Phys Biol Med. 1998;6(1):44–52.
Crossref Google Scholar
46

Daly PF, Lyon RC, Faustino PJ, Cohen JS. Phospholipid metabolism in cancer cells monitored by 31P NMR spectroscopy. J Biol Chem. 1987;262(31):14875–14878.
Crossref Google Scholar
47

Shanaiah N, Desilva MA, Gowda GN, Raftery MA, Hainline BE, Raftery D. Class selection of amino acid metabolites in body fluids using chemical derivatization and their enhanced 13C NMR. Proc Natl Acad Sci. 2007;104(28):11540–11544.
Crossref Google Scholar
48

Emwas A-HM, Salek RM, Griffin JL, Merzaban J. NMR-based metabolomics in human disease diagnosis: applications, limitations, and recommendations. Metabolomics. 2013;9(5):1048–1072.
Crossref Google Scholar
49

Duarte IF, Gil AM. Metabolic signatures of cancer unveiled by NMR spectroscopy of human biofluids. Prog Nucl Magnetic Reson Spectrosc. 2012;62:51–74.
Crossref Google Scholar
50

Ah Zhang, Sun H, Qiu S, Xj Wang. NMR-based metabolomics coupled with pattern recognition methods in biomarker discovery and disease diagnosis. Magnetic Reson Chem. 2013;51(9):549–556.
Crossref Google Scholar
51

Tiziani S, Lopes V, Günther UL. Early stage diagnosis of oral cancer using 1H NMR–based metabolomics. Neoplasia. 2009; 11(3), 269–IN210.
Crossref Google Scholar
52

Jordan KW, Cheng LL. NMR-based metabolomics approach to target biomarkers for human prostate cancer. Expert Rev Proteomics. 2007;4(3):389–400.
Crossref Google Scholar
53

DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7(1):11–20.
Crossref Google Scholar
54

Rocha CM, Carrola J, Barros AS, et al. Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of blood plasma. J Proteome Res. 2011;10(9):4314–4324.
Crossref Google Scholar
55

OuYang D, Xu J, Huang H, Chen Z. Metabolomic Profiling of serum from human pancreatic cancer patients using 1H NMR spectroscopy and principal component analysis. Appl Biochem Biotechnol. 2011;165(1):148–154.
Crossref Google Scholar
56

Slupsky CM, Steed H, Wells TH, et al. Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin Cancer Res. 2010;16(23):5835–5841.
Crossref Google Scholar
57

Dunne VG, Bhattachayya S, Besser M, Rae C, Griffin JL. Metabolites from cerebrospinal fluid in aneurysmal subarachnoid haemorrhage correlate with vasospasm and clinical outcome: a pattern-recognition 1H NMR study. NMR Biomed. 2005;18(1):24–33.
Crossref Google Scholar
58

Wei J, Xie G, Zhou Z, et al. Salivary metabolite signatures of oral cancer and leukoplakia. Int J Cancer. 2011;129(9):2207–2217.
Crossref Google Scholar
59

Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B. Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009;22(3):342–348.
Crossref Google Scholar
60

Tomlins AM, Foxall PJ, Lindon JC, et al. High resolution magic angle spinning 1H nuclear magnetic resonance analysis of intact prostatic hyperplastic and tumour tissues. Anal Commun. 1998;35(3):113–115.
Crossref Google Scholar
61

Beckonert O, Coen M, Keun HC, et al. High-resolution magic-angle-spinning NMR spectroscopy for metabolic profiling of intact tissues. Nat Protoc. 2010;5(6):1019–1032.
Crossref Google Scholar
62

Somashekar BS, Kamarajan P, Danciu T, et al. Magic angle spinning NMR-based metabolic profiling of head and neck squamous cell carcinoma tissues. J proteome Res. 2011;10(11):5232–5241.
Crossref Google Scholar
63

Sykes BD. Urine stability for metabolomic studies: effects of preparation and storage. Metabolomics. 2007;3(1):19–27.
Crossref Google Scholar
64

Bernini P, Bertini I, Luchinat C, Nincheri P, Staderini S, Turano P. Standard operating procedures for pre-analytical handling of blood and urine for metabolomic studies and biobanks. J Biomol NMR. 2011;49(3–4):231–243.
Crossref Google Scholar
65

Brown SA, Simpson AJ, Simpson MJ. Evaluation of sample preparation methods for nuclear magnetic resonance metabolic profiling studies with Eisenia fetida. Environ Toxicol Chem. 2008;27(4):828–836.
Crossref Google Scholar
66

Reily MD, Robosky LC, Manning ML, Butler A, Baker JD, Winters RT. DFTMP, an NMR reagent for assessing the near-neutral pH of biological samples. J Am Chem Soc. 2006;128(38):12360–12361.
Crossref Google Scholar
67

Grimes JH, O'Connell TM. The application of micro-coil NMR probe technology to metabolomics of urine and serum. J Biomol NMR. 2011;49(3–4):297–305.
Crossref Google Scholar
68

Canelas AB, Ras C, Ten Pierick A, van Dam JC, Heijnen JJ, Van Gulik WM. Leakage-free rapid quenching technique for yeast metabolomics. Metabolomics. 2008;4(3):226–239.
Crossref Google Scholar
69

Briscoe CJ, Hage DS. Factors affecting the stability of drugs and drug metabolites in biological matrices. Bioanalysis.2009.
Crossref Google Scholar
70

Tiziani S, Emwas A-H, Lodi A, et al. Optimized metabolite extraction from blood serum for 1H nuclear magnetic resonance spectroscopy. Anal Biochem. 2008;377(1):16–23.
Crossref Google Scholar
71

Psychogios N, Hau DD, Peng J, et al. The human serum metabolome. PLoS One. 2011;6(2):e16957.
Crossref Google Scholar
72

Rasmussen LG, Savorani F, Larsen TM, Dragsted LO, Astrup A, Engelsen SB. Standardization of factors that influence human urine metabolomics. Metabolomics. 2011;7(1):71–83.
Crossref Google Scholar
73

Beger RD. A review of applications of metabolomics in cancer. Metabolites. 2013;3(3):552–574.
Crossref Google Scholar
74

Emwas A-H, Luchinat C, Turano P, et al. Standardizing the experimental conditions for using urine in NMR-based metabolomic studies with a particular focus on diagnostic studies: a review. Metabolomics. 2015;11(4):872–894.
Crossref Google Scholar
75

Wang J, Zhang S, Li Z, et al. 1H-NMR-based metabolomics of tumor tissue for the metabolic characterization of rat hepatocellular carcinoma formation and metastasis. Tumor Biol. 2011;32(1):223–231.
Crossref Google Scholar
76
Jonsson P, Johansson AI, Gullberg J, et al. High-throughput data analysis for detecting and identifying differences between samples in GC/MS-based metabolomic analyses. Anal Chem. 2005/09/01;77(17): 5635–5642.
Crossref
77

Madsen R, Lundstedt T, Trygg J. Chemometrics in metabolomics—a review in human disease diagnosis. Anal Chim Acta. 2010;659(1):23–33.
Crossref Google Scholar
78

Kohl SM, Klein MS, Hochrein J, Oefner PJ, Spang R, Gronwald W. State-of-the art data normalization methods improve NMR-based metabolomic analysis. Metabolomics. 2012;8(1):146–160.
Crossref Google Scholar
79

Liu S-Y, Zhang R-L, Kang H, Fan Z-J, Du Z. Human liver tissue metabolic profiling research on hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterology WJG. 2013;19(22):3423–3432.
Crossref Google Scholar
80

Snow PB, Smith DS, Catalona WJ. Artificial neural networks in the diagnosis and prognosis of prostate cancer: a pilot study. J Urol. 1994;152(5 Pt 2):1923–1926.
Crossref Google Scholar
81

Lehnhardt FG, Bock C, Röhn G, Ernestus RI, Hoehn M. Metabolic differences between primary and recurrent human brain tumors: a 1H NMR spectroscopic investigation. NMR Biomed. 2005;18(6):371–382.
Crossref Google Scholar
82

Gribbestad IS, Petersen SB, Fjøsne HE, Kvinnsland S, Krane J. 1H NMR spectroscopic characterization of perchloric acid extracts from breast carcinomas and non-involved breast tissue. NMR Biomed. 1994;7(4):181–194.
Crossref Google Scholar
83

Bylesjö M, Rantalainen M, Cloarec O, Nicholson JK, Holmes E, Trygg J. OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA classification. J Chemom. 2006;20(8-10):341–351.
Crossref Google Scholar
84

Goodpaster AM, Romick-Rosendale LE, Kennedy MA. Statistical significance analysis of nuclear magnetic resonance-based metabonomics data. Anal Biochem. 2010;401(1):134–143.
Crossref Google Scholar
85

Westerhuis JA, van Velzen EJ, Hoefsloot HC, Smilde AK. Multivariate paired data analysis: multilevel PLSDA versus OPLSDA. Metabolomics. 2010;6(1):119–128.
Crossref Google Scholar
86

Molteni CG, Cazzaniga G, Condorelli DF, Fortuna CG, Biondi A, Musumarra G. Successful application of OPLS-DA for the discrimination of wild-type and mutated cells in acute lymphoblastic leukemia. QSAR Comb Sci. 2009;28(8):822–828.
Crossref Google Scholar
87

Boccard J, Rutledge DN. A consensus orthogonal partial least squares discriminant analysis (OPLS-DA) strategy for multiblock Omics data fusion. Anal Chim Acta. 2013;769:30–39.
Crossref Google Scholar
88

Ramadan Z, Jacobs D, Grigorov M, Kochhar S. Metabolic profiling using principal component analysis, discriminant partial least squares, and genetic algorithms. Talanta. 2006;68(5):1683–1691.
Crossref Google Scholar
89

Worley B, Halouska S, Powers R. Utilities for quantifying separation in PCA/PLS-DA scores plots. Anal Biochem. 2013;433(2):102–104.
Crossref Google Scholar
90

Wishart DS, Tzur D, Knox C, et al. HMDB: the human metabolome database. Nucleic acids Res. 2007;35(suppl 1):D521-D526.
Crossref Google Scholar
91

Ulrich E, Akutsu H, Doreleijers J, et al. BioMagResBank. Nucleic Acids Res. 2008;36:D402-D408.
Crossref Google Scholar
92

Forsythe IJ, Wishart DS. Exploring human metabolites using the human metabolome database. Curr Protoc Bioinforma. 2009:14.18.11-14.18.45.
Google Scholar
93

Ludwig C, Ward D, Martin A, et al. Fast targeted multidimensional NMR metabolomics of colorectal cancer. Magnetic Reson Chem MRC. 2009;47:S68-S73.
Crossref Google Scholar
94
Amiot A, Dona AC, Wijeyesekera A, et al. 1H NMR spectroscopy of fecal extracts enables detection of advanced colorectal neoplasia. J Proteome Res. 2015/09/04;14(9): 3871–3881.
Crossref
95

Piotto M, Moussallieh F-M, Dillmann B, et al. Metabolic characterization of primary human colorectal cancers using high resolution magic angle spinning 1H magnetic resonance spectroscopy. Metabolomics. 2009;5.
Crossref Google Scholar
96

Gao H, Lu Q, Liu X, et al. Application of 1H NMR-based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis. Cancer Sci. 2009;100(4):782–785.
Crossref Google Scholar
97

Shariff MI, Gomaa AI, Cox IJ, et al. Urinary metabolic biomarkers of hepatocellular carcinoma in an Egyptian population: a validation study. J Proteome Res. 2011;10(4):1828–1836.
Crossref Google Scholar
98

Carrola J, CuM Rocha, AnS Barros, et al. Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of urine. J Proteome Res. 2010;10(1):221–230.
Crossref Google Scholar
99

Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed. 2006;19(1):30–40.
Crossref Google Scholar
100
Jobard E, Pontoizeau C, Blaise BJ, Bachelot T, Elena-Herrmann B, Trédan O. A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer. Cancer Lett. 2/1/2014;343(1): 33–41.
Crossref
101

Zhang L, Jin H, Guo X, et al. Distinguishing pancreatic cancer from chronic pancreatitis and healthy individuals by 1H nuclear magnetic resonance-based metabonomic profiles. Clin Biochem. 2012;45(13–14):1064–1069.
Crossref Google Scholar
102
Jiménez B, Mirnezami R, Kinross J, et al. 1H HR-MAS NMR spectroscopy of tumor-induced local metabolic “field-effects” enables colorectal cancer staging and prognostication. J Proteome Res. 2013/02/01;12(2): 959–968.
Crossref
103
Bertini I, Cacciatore S, Jensen BV, et al. Metabolomic NMR fingerprinting to identify and predict survival of patients with metastatic colorectal cancer. Cancer Res. January 1, 2012;72(1): 356–364.
Crossref
104

Wang H, Wang L, Zhang H, et al. 1H NMR-based metabolic profiling of human rectal cancer tissue. Mol Cancer. 2013;12(1):1–12.
Crossref Google Scholar
105

Piotto M, Moussallieh F-M, Dillmann B, et al. Metabolic characterization of primary human colorectal cancers using high resolution magic angle spinning 1H magnetic resonance spectroscopy. Metabolomics. 2008;5(3):292–301.
Crossref Google Scholar
106

MuLan L, Yonghyun S, Nariya C, et al. An HR-MAS MR metabolomics study on breast tissues obtained with core needle biopsy. PLoS One. 2011;6(10):1–8.
Crossref Google Scholar
107

Sitter B, Bathen TF, Singstad TE, et al. Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy. NMR Biomed. 2010;23(4):424–431.
Crossref Google Scholar
108
Giskeødegård GF, Grinde MT, Sitter B, et al. Multivariate modeling and prediction of breast cancer prognostic factors using mr metabolomics. J Proteome Res. 2010/02/05;9(2):972–979.
Crossref
109
Asiago VM, Alvarado LZ, Shanaiah N, et al. Early detection of recurrent breast cancer using metabolite profiling. Cancer Res. November 1, 2010;70(21): 8309–8318.
Crossref
110
Carrola J, Rocha CM, Barros AS, et al. Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of urine. J Proteome Res. 2011/01/07;10(1): 221–230.
Crossref
111

Liu Y-F, Xu S, Gong H, Cui Y-F, Song D-D, Zhou Y-P. Partial least-squares discriminant analysis optimized by particle swarm optimization: application to 1H nuclear magnetic resonance analysis of lung cancer metabonomics. J Chemom. 2015;29(10):537–546.
Crossref Google Scholar
112

Chen W, Zu Y, Huang Q, et al. Study on metabonomic characteristics of human lung cancer using high resolution magic-angle spinning 1H NMR spectroscopy and multivariate data analysis. Magnetic Reson Med. 2011;66(6):1531–1540.
Crossref Google Scholar
113

Duarte IF, Rocha CM, Barros AS, et al. Can nuclear magnetic resonance (NMR) spectroscopy reveal different metabolic signatures for lung tumours? Virchows Arch. 2010;457(6):715–725.
Crossref Google Scholar
114

Jordan KW, Adkins CB, Su L, et al. Comparison of squamous cell carcinoma and adenocarcinoma of the lung by metabolomic analysis of tissue–serum pairs. Lung Cancer. 2010;68(1):44–50.
Crossref Google Scholar
115
Rocha CM, Barros AS, Gil AM, et al. Metabolic profiling of human lung cancer tissue by 1H high resolution magic angle spinning (HRMAS) NMR spectroscopy. J Proteome Res. 2010/01/04;9(1): 319–332.
Crossref
116
Yang Y, Li C, Nie X, et al. Metabonomic studies of human hepatocellular carcinoma using high-resolution magic-angle spinning 1H NMR Spectroscopy in conjunction with multivariate data analysis. J Proteome Res. 2007/07/01;6(7): 2605–2614.
Crossref
117
Nahon P, Amathieu R, Triba MN, et al. Identification of serum proton NMR metabolomic fingerprints associated with hepatocellular carcinoma in patients with alcoholic cirrhosis. Clin Cancer Res. December 15, 2012;18(24): 6714–6722.
Crossref
118

Solinas A, Chessa M, Culeddu N, et al. High resolution-magic angle spinning (HR-MAS) NMR-based metabolomic fingerprinting of early and recurrent hepatocellular carcinoma. Metabolomics. 2013;10(4):616–626.
Crossref Google Scholar
119
Bathe OF, Shaykhutdinov R, Kopciuk K, et al. Feasibility of Identifying pancreatic cancer based on serum metabolomics. Cancer Epidemiol Biomark Prev. January 1, 2011;20(1): 140–147.
Crossref
Genes & Diseases
Volume 4 Issue 1,
March 2017
Pages 28-36
DOI: 10.1016/j.gendis.2016.12.001
Cite this article:
Li T, Deng P. Nuclear Magnetic Resonance technique in tumor metabolism. Genes & Diseases, 2017, 4(1): 28-36. https://doi.org/10.1016/j.gendis.2016.12.001

246

Views

1

Downloads

16

Crossref

N/A

Web of Science

20

Scopus

0

CSCD

Altmetrics
Received: 11 September 2016
Accepted: 05 December 2016
Published: 13 December 2016
© 2016, Chongqing Medical University.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Return